There are several investigational treatments that are being tested in various sub-studies as part of the LUNGMAP screening trial. This trial is for patients who have already received the information on the results of the biomarker testing as part of the LUNGMAP screening trial. Patients eligible for this study have a tumor sample that did not have a biomarker that matches one of the treatment studies that are open or because you were not a candidate for a biomarker-matched treatment study. For this sub-study, patients will be assigned to treatment with either the usual treatment, which is the
current standard of care drug (docetaxel, gemcitabine, pemetrexed [for
non-squamous cell Non-small cell lung cancer only], or ramucirumab combined with docetaxel) or to the investigational therapy (ramucirumab combined with pembrolizumab).
Immunotherapy with monoclonal antibodies, such as ramucirumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in standard of care chemotherapy for non-small cell lung cancer, such as docetaxel, gemcitabine hydrochloride, and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ramucirumab and pembrolizumab together may work better in treating patients with non-small lung cancer compared to standard of care.
This sub-study is associated with the LUNGMAP screening protocol.
Click here for more information from the National Cancer Institute.
LOCATIONS:
1. Genesis Cancer Care Institute
1401 W. Central Park Ave.
Davenport, IA 52804
Phone Number: 563-421-1900
2. Genesis Cancer Clinic-Silvis
801 Illini Dr.
Silvis, IL 61282
Phone Number: 563-421-1900
3. Iowa Cancer Specialists
1750 E. 53rd St.
Davenport, IA 52807
Phone Number: 563-345-4325
Call ahead with COVID-19 symptoms or exposure. Learn more about COVID-19. COVID-19 Vaccine Information
